IMUX IMUX
Company Profile ↓Company Overview
IMUX (IMUX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.00.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +43.25% |
| 6 Months: | +113.57% |
| 3 Months: | +24.20% |
| 1 Month: | -8.79% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)47.54 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -14.82M | -15.08M | -12.34M | - | -9.66M | -9.55M | -10.24M | -12.69M | -12.55M | -12.64M | - | -14.49M | -2.67M | -1.80M | - | -4.66M | -15.01M | -9.18M | - | -9.01M | -12.22M | -13.54M | - | -32.39M | -19.17M | -18.39M | - | -21.43M | -20.61M | -20.12M | -27.25M | -25.02M | -23.57M | -23.88M | -22.81M | -25.73M | -26.82M | -27.08M | -25.99M | -33.23M |
| Net Income | -14.76M | -15.11M | -12.30M | -9.86M | -9.59M | -9.47M | -10.18M | -12.60M | -12.41M | -12.48M | -14.59M | -2.26M | -2.67M | -1.80M | -4.81M | -4.31M | -14.71M | -8.21M | -7.69M | -8.49M | -11.46M | -12.91M | -11.16M | -34.53M | -17.93M | -19.29M | -21.18M | -20.81M | -21.90M | -21.22M | -25.27M | -24.00M | -22.77M | -29.58M | -21.38M | -24.37M | -25.47M | -26.82M | -25.58M | -32.59M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.79 | -0.90 | -0.70 | -0.53 | -1.63 | -0.82 | -0.76 | -0.81 | -0.74 | -0.72 | -0.69 | -0.58 | -0.54 | -0.51 | -0.30 | -0.21 | -0.24 | -2.51 | -0.20 | -0.13 | -1.08 |
| R&D Expense | 11.75M | 11.54M | 9.65M | - | 6.86M | 6.86M | 7.47M | 9.63M | 9.83M | 9.69M | - | 10.16M | 2.16M | 1.41M | - | 3.35M | 6.03M | 7.10M | - | 6.43M | 9.99M | 11.04M | - | 11.52M | 15.74M | 15.48M | - | 17.45M | 16.54M | 16.54M | 22.96M | 21.17M | 19.80M | 18.74M | 18.32M | 21.37M | 21.53M | 21.37M | 20.01M | 25.63M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -9.58M | -31.40M | -50.34M | -52.12M | -41.27M | -52.66M | -12.00M | -37.03M | -48.97M | -91.67M | -119.49M | -99.22M | -98.05M | -103.23M |
| Net Income | -6.70M | -32.72M | -47.67M | -52.02M | -40.97M | -52.08M | -11.54M | -34.93M | -44.02M | -92.94M | -120.41M | -93.61M | -100.51M | -97.17M |
| Diluted EPS | - | - | - | - | - | - | - | - | -2.81 | -3.93 | -3.78 | -2.11 | -1.00 | -0.62 |
| R&D Expense | 5.10M | 21.79M | 39.48M | 39.77M | 30.05M | 39.34M | 9.60M | 22.51M | 38.64M | 61.12M | 71.25M | 83.22M | 80.05M | 81.98M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 46.59M | 108.08M | 89.08M | 64.03M | 60.38M | 13.37M | 65.95M | 167.86M | 139.10M | 127.75M | 54.30M | 40.87M | 24.05M |
| Total Equity | -54.85M | -7.63M | -44.66M | 97.56M | 82.33M | 58.45M | -13.34M | -25.74M | 58.36M | 158.78M | 127.11M | 113.68M | 28.93M | 18.43M | -6.67M |
| Cash & Equivalents | 803.00K | 4.48M | 38.19M | 102.24M | 83.42M | 59.99M | 56.90M | 13.07M | 29.37M | 127.45M | 86.86M | 106.75M | 46.67M | 35.67M | 15.48M |
| Total Liabilities | - | - | - | - | - | - | - | 1.92M | 7.59M | 9.08M | 11.98M | 14.07M | 25.37M | 22.44M | 30.73M |
| Current Liabilities | - | - | 7.45M | 10.28M | 6.66M | 5.48M | 10.28M | 1.92M | 7.07M | 8.40M | 11.40M | 13.08M | 24.73M | 22.18M | 30.62M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | -35.77M | -40.40M | -9.74M | -28.55M | -46.12M | -83.23M | -65.14M | -70.83M | -84.77M | -85.81M |
| Investing Cash Flow | - | - | - | - | -21.00K | -678.00K | -32.00K | 10.54M | -146.00K | -67.00K | -9.74M | 9.46M | -264.00K | -161.00K |
| Financing Cash Flow | - | - | - | - | 12.37M | 37.98M | 19.26M | 34.90M | 144.43M | 42.84M | 95.76M | 1.03M | 74.54M | 65.58M |
| Capital Expenditure | -261.00K | -1.48M | -1.41M | -2.34M | -556.00K | -685.00K | -32.00K | -55.00K | -146.00K | -67.00K | -112.00K | -334.00K | -264.00K | -161.00K |
| Free Cash Flow | - | - | - | - | -36.33M | -41.08M | -9.77M | -28.60M | -46.27M | -83.30M | -65.26M | -71.16M | -85.03M | -85.97M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 87.8% | 73.3% | -48.9% | -63.2% | -70.1% | 390.5% | 44.8% | -59.9% | -27.7% | -73.1% | -105.9% | -323.6% | -545.4% | 1,456.2% |
| ROCE % | - | -80.2% | -51.5% | -63.2% | -70.5% | -105.1% | -104.8% | -62.9% | -30.7% | -71.8% | -104.2% | -335.6% | -524.5% | 1,572.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IMUX
Immunic, Inc. Announces 1-for-10 Reverse Stock Split - PR Newswire
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNbG1xN2FKT0dlWGlCeTFtek5famlZbXlXN2dkS1NDdVJ1NmE3VHJFblV0VlFkV2JkaFc3SmJCWDdGR250VXRjVTdZaDRQbGo2VjNXSDloeEpEMWg3RXJuQXBpQzMxb0M3WGNFZmpudl8wMXlyODlwODV1blhjeFJBc1hSQkZLQVlDcVdVRX…
AMAT Stock On Track To Open At An All-Time High – This Analyst Sees A Potential 37% Upside For The Shares - Stocktwits
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQVTlXd0F4X1lQdy0zanZuQV9CR1J3ZWtrWGFWUlNaYmdpb0h1RVJTMnk1bzVUSVVMcjlldktkdWc3ZV9IRk40Qld1dmhJQkNBa1lnekJKSkV6ek9MOC1qbENOWVVYblRQZGxhelF1a1hxWEw0QnhreXpNTFo2eFI0bDhTd0M0MHFWaFBQWm…
IMUX Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFAyd3AwaEExSEszMl9Lb2FON0l1bnVnd29Dc181YTFlTHJwSVEwd09xcnFoZ2F1bEhiWkMwVW81aV9hX01yVUl1YXVWUUpVR0FqX01ZN0RNcTU0Y0NCR3lqUDk1dFdZa3BMVnlBcFpjZmxJNV9rRXIzd3JB?oc=5" target="_blank">IMU…
Ocrevus launch veteran Erik Lundgren takes over at Immunic - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxORHBDMzdxak9RX3VXMEJqS05QOENXZk1DTkZYbU9EVlJxNi1rc1dPMHdiRWM2V0FkTjFLYTIzWmxVd3R6WGk0T0IzN05YSUpGbUtwdnRvMm1IbEwyS3B2SDJYMTlKbHRCTFZDMTdGaGpMNEcyMHhjbjRIUHJINE5aTnFmZ0U0WnJ0NmcybE…
Immunic (IMUX) Reviews 2025 Performance and Highlights Upcoming Milestones, Shares Up 24.10% - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxPdXhvTkVJWmllN1FDRWNOaXBCQlE0MzBzRnU0UTR0a3BNdThnX1BkRDFfOHdJUEZXZWtYZVd0d1VSeEptcWItenVaU19sOWJvLWxZSTRncFRIQ1VTdVhsZDMzX2ZUcEx0S3RpdUxYeW01a1NOZkNadHdTbWQzY0dPZ05tMHl3amhsdE9j?o…
IMMUNIC ($IMUX) Releases Q1 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxNcW5UN3BFZmpJT2FTWVd1S0VXQVdoUWt5ODhWQ3pmeFQ3ZVVOU01CZG1jOW91UkdERGZvcWkzUkRBY0U1bkxKWE1yTFg1VUhwVllYN0Q1azJGTDZ0NzFESnJOUG1jV0JGTWJTaWkyd2lFdmxLZUdEUzRNUjV0VEpXWi1lUUx2RlU?oc=5" …
IMUX — Frequently Asked Questions
What is the current share price of IMUX?
As of 2026-08-05 17:25 PDT, IMUX trades at $14.01 on NASDAQ/NYSE. Its 52-week range is $5.10 to $15.41.
What is the P/E ratio of IMUX?
IMUX trades at a trailing price-to-earnings (P/E) ratio of -22.60.
Is IMUX a good stock to buy?
This page provides a data-driven analysis of IMUX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.